Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

M Maio; A Scherpereel; L Calabro; Joachim Aerts; SC Perez; A Bearz; K Nackaerts; DA Fennell; D Kowalski; AS Tsao; P Taylor; F Grosso; SJ Antonia; AK Nowak; M Taboada; M Puglisi; PK Stockman; HL Kindler

doi:10.1016/s1470-2045(17)30446-1

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

M Maio, A Scherpereel, L Calabro, Joachim Aerts, SC Perez, A Bearz, K Nackaerts, DA Fennell, D Kowalski, AS Tsao, P Taylor, F Grosso, SJ Antonia, AK Nowak, M Taboada, M Puglisi, PK Stockman, HL Kindler

Pulmonary Medicine

Research output: Contribution to journal › Article › Academic › peer-review

321 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1261-1273
Number of pages	13
Journal	Lancet Oncology
Volume	18
Issue number	9
DOIs	https://doi.org/10.1016/s1470-2045(17)30446-1
Publication status	Published - 2017

Access to Document

10.1016/s1470-2045(17)30446-1

http://hdl.handle.net/1765/101295

Cite this

Maio, M., Scherpereel, A., Calabro, L., Aerts, J., Perez, SC., Bearz, A., Nackaerts, K., Fennell, DA., Kowalski, D., Tsao, AS., Taylor, P., Grosso, F., Antonia, SJ., Nowak, AK., Taboada, M., Puglisi, M., Stockman, PK., & Kindler, HL. (2017). Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncology, 18(9), 1261-1273. https://doi.org/10.1016/s1470-2045(17)30446-1

@article{c61b441b6549476f8d546e1073119fae,

title = "Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial",

author = "M Maio and A Scherpereel and L Calabro and Joachim Aerts and SC Perez and A Bearz and K Nackaerts and DA Fennell and D Kowalski and AS Tsao and P Taylor and F Grosso and SJ Antonia and AK Nowak and M Taboada and M Puglisi and PK Stockman and HL Kindler",

year = "2017",

doi = "10.1016/s1470-2045(17)30446-1",

language = "Undefined/Unknown",

volume = "18",

pages = "1261--1273",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "9",

}

Maio, M, Scherpereel, A, Calabro, L, Aerts, J, Perez, SC, Bearz, A, Nackaerts, K, Fennell, DA, Kowalski, D, Tsao, AS, Taylor, P, Grosso, F, Antonia, SJ, Nowak, AK, Taboada, M, Puglisi, M, Stockman, PK & Kindler, HL 2017, 'Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial', Lancet Oncology, vol. 18, no. 9, pp. 1261-1273. https://doi.org/10.1016/s1470-2045(17)30446-1

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. / Maio, M; Scherpereel, A; Calabro, L et al.
In: Lancet Oncology, Vol. 18, No. 9, 2017, p. 1261-1273.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

AU - Maio, M

AU - Scherpereel, A

AU - Calabro, L

AU - Aerts, Joachim

AU - Perez, SC

AU - Bearz, A

AU - Nackaerts, K

AU - Fennell, DA

AU - Kowalski, D

AU - Tsao, AS

AU - Taylor, P

AU - Grosso, F

AU - Antonia, SJ

AU - Nowak, AK

AU - Taboada, M

AU - Puglisi, M

AU - Stockman, PK

AU - Kindler, HL

PY - 2017

Y1 - 2017

U2 - 10.1016/s1470-2045(17)30446-1

DO - 10.1016/s1470-2045(17)30446-1

M3 - Article

SN - 1470-2045

VL - 18

SP - 1261

EP - 1273

JO - Lancet Oncology

JF - Lancet Oncology

IS - 9

ER -